Clofarabine in the treatment of acute myeloid leukemia in older adults

Therapeutic Advances in Hematology

Volumn 4, Issue 1, 2013, Pages 5-13

  Tiley, Stephen ^a   Claxton, David ^b  

^a Est Carolina University   (Liberia)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukemia; clofarabine; older adults

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSOLIDATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; GERIATRIC CARE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; LIVER FUNCTION; LIVER FUNCTION TEST; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; REVIEW; SENESCENCE; SEPSIS; SEPTICEMIA; SIDE EFFECT; TIME TO TREATMENT; TREATMENT DURATION;

EID: 84993734730     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712461666     Document Type: Article

References (16)

1. Agura E. Cooper B. Holmes H. Vance E. Berryman R. Maisel C. et al. (2011) Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. The Oncologist 16: 197–206.
2. Burnett A. Russell N. Kell J. Dennis M. Milligan D. Paolini S. et al. (2010) European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 28: 2389–2395.
3. Claxton D. Erba H. Faderl S. Arellano M. Lyons R. Kovacsovics T. et al. CLASSIC II Investigators (2012) Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma 53: 435–440.
4. Erba H. (2007) Prognostic factors in elderly patients with AML and the implications for treatment. Hematology Am Soc Hematol Educ Program 420–428.
5. Faderl S. Ferrajoli A. Wierda W. Huang X. Verstovsek S. Ravandi F. et al. (2008 a) Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113: 2090–2096.
6. Faderl S. Gandhi V. O'Brien S. Bonate P. Cortes J. Estey E. et al. (2005) Results of a phase 1–2 study of clofarabine in combination with cytarabine (Ara-C) in relapsed and refractory acute leukemias. Blood 105: 940–947.
7. Faderl S. Ravandi F. Huang X. Garcia-Manero G. Ferrajoli A. Estrov Z. et al. (2008 b) A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112: 1638–1645.
8. Faderl S. Ravandi F. Huang X. Wang X. Jabbour E. Garcia-Manero G. et al. (2012) Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 26 January (Epub ahead of print).
9. Faderl S. Verstovsek S. Cortes J. Ravandi F. Beran M. Garcia-Manero G. et al. (2006) Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108: 45–51.
10. Garcia-Manero G. Kantarjian H. Sanchez-Gonzalez B. Yang H. Rosner G. Verstovsek S. et al. (2006) Phase 1 / 2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108: 3271–3279.
11. Griffiths E. (2007) Acute myeloid leukemia: risk stratification and therapy selection in the era of molecular diagnostics. Mol Oncol Rep 1: 2012.
12. Kantarjian H. Erba H. Claxton D. Arellano M. Lyons R. Kovascovics T. et al. (2010) Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28: 549–555.
13. Kantarjian H. Gandhi V. Cortes J. Verstovsek S. Du M. Garcia-Manero G. et al. (2003) Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102: 2379–2386.
14. Kantarjian H. Jeha S. Gandhi V. Wess M. Faderl S. (2007) Clofarabine: past, present, and future. Leuk Lymphoma 48: 1922–1930.
15. Leith C. Kopecky K. Godwin J. McConnell T. Slovak M. Chen I. et al. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323–3329.
16. Tran H. Yang D. (2012) Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults. Ann Pharmacother 46: 89–96.